Another Renowned Scientist Questions The Safety Of Hpv Vaccines

Another Renowned Scientist Questions The Safety of HPV Vaccines

A number of prominent doctors and scientists have shared their criticisms in peer-reviewed publications for quite some time. These opinions are obviously not promoted at all, and anybody who makes such criticisms of the “medical establishment” is usually vilified.

by Arjun Walia, guest writer

In the past, it took a lot of bravery to say what you really felt if it was a perspective that ‘went against the grain.’

Today, it seems to be easier for health professionals to do so given the fact that so many have done it in the past and more are continuing to do it.

Another Renowned Scientist Questions The Safety Of Hpv Vaccines

I’ve written about this before, using multiple examples. Dr. Marcia Angell, physician and longtime Editor-in-Chief of the New England Medical Journal (NEMJ), said that “it is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of The New England Journal of Medicine.” (source)

Arnold Seymour Relman (1923-2014), a Harvard professor of medicine and also a former Editor-in-Chief of NEMJ, was frustrated that “the medical profession is being bought by the pharmaceutical industry, not only in terms of the practice of medicine, but also in terms of teaching and research. The academic institutions of this country are allowing themselves to be the paid agents of the pharmaceutical industry. I think it’s disgraceful.” (source)

The list of papers that dive into the corruption and what seems to be the modern day politicization of science is long.

“Even the pharmaceutical companies have been able to purchase congress. They’re the largest lobbying entity in Washington D.C.. They have more lobbyists in Washington D.C. than there are congressman and senators combined.

“They give twice to congress what the next largest lobbying entity is, which is oil and gas… Imagine the power they exercise over both republicans and democrats.

“They’ve captured them (our regulatory agencies) and turned them into sock puppets. They’ve compromised the press… and they destroy the publications that publish real science.” – Robert F. Kennedy Jr. (source)

The latest paper I came across expressing the same thing was published in 2016 by Dr. Mahin Khatami, who is a former program director at the National Cancer Institute (NCI) and National Institutes of Health (NIH).

This particular paper of hers, titled “Safety concerns and hidden agenda behind HPV vaccines: another generation of drug-dependent society,” was published in Clinical and Translational Medicine. (PMC5138175)

In it, she makes many bold statements like:

“The establishment is entitled to glamorize and publicize too many drugs or vaccines with little/no ethical or safety considerations for short, or long-term health hazards of such projects… Majority of vaccines that were designed to prevent diseases caused more death and diseases than public exposures to infective agents.

“Policy makers and the public should take a closer look at the long-lasting ‘medical/scientific ponzi schemes’ that the cancer establishment created to control a drug-dependent sick society.”

She states quite clearly in her introduction that the purpose of modern day healthcare, according to her, is as follows:

“Formation of a highly ordered and sophisticated medical hierarchy (establishment) in the nineteenth/twentieth century within higher education institutions (e.g., medical schools, organizations) was supported by businessmen and philanthropists with motives to profit from the sale of drugs.”

Is there any truth to what she is saying, or any corroborating research other than the sources she uses in her paper? Let’s take a look at her statement that “too any vaccines with little/no ethical or safety considerations” are being pushed on the population. When it comes to the HPV vaccine, “sixty-nine cancer centers urged HPV vaccination and thus-far, 80 million doses of HPV vaccines ($200–260/ dose) consumed by healthy public” in the United States. I’ll let you do the math. (source)

A new study published in The Royal Society of Medicine is one of multiple studies over the years that has emerged, questioning the efficacy of the HPV vaccine.

The researchers conducted an appraisal of published phase 2 and 3 efficacy trials in relation to the prevention of cervical cancer and their analysis showed “the trials themselves generated significant uncertainties undermining claims of efficacy” in the data they used.

The researchers emphasized that “it is still uncertain whether human papillomavirus (HPV) vaccination prevents cervical cancer as trials were not designed to detect this outcome, which takes decades to develop.”

The researchers point out that the trials used to test the vaccine may have “overestimated” the efficacy of the vaccine.

A study published in 2013 in Current Pharmaceutical Design carried out a review of HPV vaccine pre- and post-licensure trials to assess the evidence of their effectiveness and safety. They found that,

HPV vaccine clinical trials design, and data interpretation of both efficacy and safety outcomes, were largely inadequate. Additionally, we note evidence of selective reporting of results from clinical trials (i.e., exclusion of vaccine efficacy figures related to study subgroups in which efficacy might be lower or even negative from peer-reviewed publications).

Given this, the widespread optimism regarding HPV vaccines long-term benefits appears to rest on a number of unproven assumptions (or such which are at odds with factual evidence) and significant misinterpretation of available data.

For example, the claim that HPV vaccination will result in approximately 70% reduction of cervical cancers is made despite the fact that the clinical trials data have not demonstrated to date that the vaccines have actually prevented a single case of cervical cancer (let alone cervical cancer death), nor that the current overly optimistic surrogate marker-based extrapolations are justified.

Likewise, the notion that HPV vaccines have an impressive safety profile is only supported by highly flawed design of safety trials and is contrary to accumulating evidence from vaccine safety surveillance databases and case reports which continue to link HPV vaccination to serious adverse outcomes (including death and permanent disabilities).

A study published in Clinical Rheumatology entitled “Serious adverse events after HPV vaccination: a critical review of randomized and post-marketing case series” also brings up concerns:

HPV vaccine randomized trials were identified in PubMed. Safety data were extracted. Post-marketing case series describing HPV immunization adverse events were reviewed. Most HPV vaccine randomized trials did not use inert placebo in the control group.

Two of the largest randomized trials found significantly more severe adverse events in the tested HPV vaccine arm of the study. Is The Aluminum In HPV Vaccines The Issue?

The list is quite long when it comes to the HPV vaccine, so Khatami is not incorrect in her opinion.

Even those from within our federal health regulatory agencies are speaking up.

In fact, only a few years ago, more than a dozen scientists from within the CDC put out an anonymous public statement detailing the influence corporations have on government policies. They were referred to as the Spider Papers.

Final Thoughts

In her paper, Khatami brings up a number of examples with regards to different vaccines and goes deeper into the “medical establishment” and “hidden agendas” of the medical industry, claiming that this is a big problem because it’s not about the health and well-being of people, but rather large corporate profits, and it’s coming at the expense of our health.

I suggest you read it if you want to go a little deeper into the topic than this article does, because what was presented in this article is simply a tidbit of what she expressed in this particular publication.